Additionally, two distinct clinical trials have demonstrated that the methylation status of the MGMT promoter can serve as an indicator of the prognosis of glioma patients treated with TMZ, but not when treated with the chemotherapy regimen comprising procarbacine, lomustine (BCNU), and vincristine (PCV) [136,137]. Here, MGMT is linked to central nervous system cancer.